Samsung Gets Review of Alexion Blood Disorder Treatment Patents

Samsung Bioepis Co. Ltd. convinced an administrative tribunal to take up challenges to three Alexion Pharmaceuticals Inc. patents covering an antibody and method used to treat a blood disorder.

The biotechnology company sufficiently demonstrated that AstraZeneca-subsidiary Alexion’s US Patent Nos. 9,732,149, 9,718,880, and 9,725,504 could be unpatentable due to anticipation or obviousness, the Patent Trial and Appeal Board said in three decisions issued Dec. 8 instituting reviews of the three patents’ eligibility.

Alexion’s inventions include a “non-naturally occurring, uniquely-engineered humanized antibody” and ways to use the antibody to treat paroxysmal nocturnal hemoglobinuria, according to the decisions. Paroxysmal ...